Pioneering remote patient monitoring for Parkinson's disease and other movement disorders

The Market: The Parkinson's disease (PD) treatment market is expected to reach $12.1B by 2030.

Problem: PD is extremely complex for clinicians to manage with the tools they have. Sporadic clinical visits provide limited information about the patient's daily experience and optimizing therapy can take years of repeated office visits to get dosing just right. Then as the disease progresses the process starts all over.

Solution: Our FDA-cleared and CE-marked KinesiaU™ motor assessment system provides an opportunity to bring remote patient monitoring to movement disorders. Based on our previous Kinesia systems, validated in the research market and used commercially at hundreds of clinical sites in research studies, KinesiaU uses a smartwatch and our proprietary algorithms to remotely monitor motor symptoms.

KinesiaU is reimbursable as part of remote patient monitoring creating a new revenue stream for clinicians. Clinical trials demonstrate that the technology can help clinicians remotely adjust medication, personalize medication schedules, improve therapy compliance, identify candidates for advanced therapies such as deep brain stimulation (DBS) and drug pumps, and increase referrals to specific therapies.

Intellectual Property: Kinesia technology is well protected by an extensive portfolio of issued US and international patents covering real-time monitoring and data transfer, artificial intelligence for quantifying symptom severities, adjusting medication, drug pump, or neuromodulation therapy based on motor assessment, and automated therapy adjustment.

Financial Overview: The Kinesia technology has been developed and proven in the research market using $40M in non-dilutive funds. The technology is ready now to bring remote patient monitoring to movement disorders.

- *FDA-cleared and CE-marked*
- *Real-time motor symptom data for patients and providers*
- *Clinically validated*
- *Optimize therapy remotely*
- *Personalize medication schedules*
- *Increase therapy referrals*
- *Improve therapy compliance*
- *Identify advanced therapy candidates*
- *Reimbursable as part of remote patient monitoring*
- *Recommended by NICE in the UK*
- *Extensive patent protection*
- *Proven commercially successful in the research market*

Point of Contact
Dustin A. Heldman, PhD
President and COO
dheldman@glneurotech.com
216-361-5410

Management Team
Robert N. Schmidt, Chairman and CEO
Brian M. Kolkowski, Exec. VP & Gen. Counsel

Accurate and Reliable
Assessment of Parkinson's Disease

KinesiaU™
MOTOR ASSESSMENT SYSTEM